CDMO Serán Bioscience announced “a strategic growth transaction” led by Bain Capital Life Sciences that is worth more than $200 million, with the funds intended to support completion of a new commercial-scale manufacturing facility in Bend, Oregon, where the company is headquartered. According to Serán Bio, the commercial-scale facility, which is expected to be finished in 2026, will include inhaled and nasal drug delivery manufacturing capabilities, including spray drying, nano-milling, and powder filling.
In 2021, Vivo Capital acquired a majority stake in Serán, which currently employs approximately 200 people, including 150 scientists and engineers, according to Serán. The company says that it intends to hire up to 150 more employees as part of the new expansion.
Serán CEO Dan Smithey commented, “This transaction is a significant milestone in Serán’s evolution, which will enable us to rapidly scale our clinical manufacturing capability to support launches of new medicines, as well as serve new clients seeking state-of-the-art commercial capacity. We are proud to have the additional support and resources of a preeminent life sciences investor in Bain Capital who shares our vision for expanding Serán’s science-based drug development capabilities to enable commercial manufacturing of complex medicines.”
Read the Serán Bioscience press release.
